CanpolatUKocyigitDYildirimA. Role of endothelial dysfunction and endocan in atherosclerosis: point of origin or end point?Angiology. 2016. doi:10.1177/0003319716654627.
2.
CimenTEfeTHAkyelA, et al.Human endothelial cell-specific molecule-1 (endocan) and coronary artery disease and microvascular angina. Angiology. 2016. doi:10.1177/0003319715625827.
3.
SarrazinSAdamELyonM, et al.Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta. 2006;1765:25–37.
4.
CoxLAvan EijkLTRamakersBP, et al.Inflammation-induced increases in plasma endocan levels are associated with endothelial dysfunction in humans in vivo. Shock. 2015;43:322–326.
5.
ScherpereelADepontieuFGrigoriuB, et al.Endocan, a new endothelial marker in human sepsis. Crit Care Med. 2006;34:532–537.
6.
BechardDScherpereelAHammadH, et al.Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol. 2001;167:3099–3106.
7.
WatanabeTFanJ. Atherosclerosis and inflammation mononuclear cell recruitment and adhesion molecules with reference to the implication of ICAM-1/LFA-1 pathway in atherogenesis. Int J Cardiol. 1998;66:S45–S53; discussion S55.
8.
HalcoxJPSchenkeWHZalosG, et al.Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002;106:653–658.
